Current quadruple and alternate therapies yielded poor eradication rates ( < 70 % ) , but the latter produced marked symptomatic improvement , both for participants in whom H pylori was eradicated and for those in whom it was not eradicated , pointing out its potential use with patients with functional dyspepsia ( FD ) who are both positive and negative for H pylori .